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ABSTRACT
Introduction: There is an urgent need to
develop new drugs to treat malaria due to
increasing resistance to first-line therapeutics
targeting the causative organism, Plasmodium
falciparum (P. falciparum). One drug candidate is
DM1157, a small molecule that inhibits the
formation of hemozoin, which protects P. falciparum from heme toxicity. We describe a firstin-human, phase 1 trial of DM1157 in healthy
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adult volunteers that was halted early because
of significant toxicity.
Methods: Adverse events were summarized
using descriptive statistics. We used pharmacokinetic modeling to quantitatively assess
whether the DM1157 exposure needed for P.
falciparum inhibition was achievable at safe
doses.
Results: We found that there was no dose
where both the safety and efficacy target were
simultaneously achieved; conversely, the model
predicted that 27 mg was the highest dosage at
which patients would consistently maintain
safe exposure with multiple dosing. By predefining dose escalation stopping rules and
conducting an interim pharmacokinetic/pharmacodynamic analysis, we determined that the
study would be unable to safely achieve a
dosage needed to observe an anti-malarial
effect, thereby providing strong rationale to
halt the study.
Conclusion: This study provides an important
example of the risks and challenges of conducting early phase research as well as the role
of modeling and simulation to optimize participant
safety
(ClinicalTrials.gov,
NCT03490162).
Keywords: Clinical trials; Drug safety; Malaria;
Pharmacokinetics; Plasmodium falciparum
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Key Summary Points
We describe a first-in-human, phase 1 trial
of of an anti-malarial drug in healthy
adult volunteers that was halted early
because of significant toxicity
By pre-defining dose escalation stopping
rules and conducting an interim
pharmacokinetic/pharmacodynamic
analysis, we determined that the study
would be unable to safely achieve a dosage
needed to observe an anti-malarial effect
This study provides an important example
of the risks and challenges of conducting
early phase research as well as the role of
modeling and simulation to optimize
participant safety

INTRODUCTION
Malaria is a substantial global health crisis
causing more than 400,000 deaths annually [1].
As a result of rising resistance to first-line therapeutics targeted at the most deadly causative
organism, Plasmodium falciparum (P. falciparum),
there is an urgent need to develop new treatments for malaria. One such drug candidate is
DM1157, a small molecule that inhibits the
formation of hemazoin, which protects P. falciparum from heme toxicity [2]. In addition,
DM1157 has the additive advantage of competitively inhibiting the chloroquine resistance
transporter
(PfCRT),
thereby
potentially
impairing drug efflux and overcoming common
resistance mechanisms in P. falciparum. In vitro
studies demonstrated that DM1157 had minimum 50% inhibitory concentrations (IC50)
between 0.9 and 1.8 nM against laboratory
strains of P. falciparum and was potent against
39 clinical isolates, most of which were resistant
to chloroquine.
DM1157 is an analog of chloroquine bound
to a dipyridinylmethylamino piperidinyl moiety. Preclinical pharmacokinetic (PK) and

metabolism studies in rat and cynomolgus
monkey indicate oral DM1157 is rapidly absorbed and has relatively high bioavailability. In
these species, DM1157 accumulates in erythrocytes and undergoes hepatic metabolism, and
concentrations increase in a greater-than-proportional manner relative to dose, suggesting
non-linear kinetics. In a non-GLP (Good Laboratory Practice) microsomal stability study, the
half-life for DM1157 in liver microsomes from
rat, cynomolgus monkey and humans
was [ 60 min with an estimated intrinsic clearance of \ 115.5 ll/min/mg. In a non-GLP
in vitro metabolite identification study,
DM1157 is metabolized to 18 metabolites in rat,
cynomolgus monkey and human liver microsomes. All major metabolites produced by
human liver microsomes are also produced by
rat and cynomolgus monkey liver microsomes.
The half-life of DM1157 was 6.5–13.7 h in
cynomolgus monkeys, supporting the testing of
once daily dosing in humans. The preclinical
toxicity studies demonstrated dose-limiting
gastrointestinal intolerance, weight loss,
lethargy, reversible elevation in liver enzymes
and a systemic inflammatory response consisting of elevations in neutrophils, monocytes,
fibrinogen and globulins. The inflammatory
response, which occurred in animals at dosages
of 10 mg/kg/day and 80 mg/kg/day, lacked
microscopic correlates. Additionally, there was
potential for QTc prolongation based on in vitro
human ether-a-go-go (hERG) channel activation. Overall, the constellation of findings was
similar to the known and expected class effects
for chloroquine and related molecules. A no
observed adverse event level dose was determined to be 9 mg/kg in rat and 10 mg/kg in
cynomolgus monkey; standard conversion factors for human equivalent doses and a further
safety factor of tenfold were applied to select a
maximal clinical starting dose of 0.145 mg/kg
for this study.
DM1157 was evaluated in a first-in-human,
phase 1 trial that was terminated because of
significant toxicity in healthy adult volunteers.
Due to the need to raise awareness of drug
toxicity that can occur during clinical trials, we
aimed to present a study overview with an
emphasis on safety outcomes for DM1157 and
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the use of PK/pharmacodynamics (PD) modeling and simulation to inform phase 1 clinical
trial decision-making.

METHODS
Study Synopsis
The study was a phase 1, randomized, doubleblind, single site and placebo-controlled study of
DM1157 in healthy adult volunteers (ClinicalTrials.gov, NCT03490162). Briefly, the study
was designed in three parts; part 1 assessed the
single ascending dose (SAD) DM1157 in seven
cohorts (6 active drug and 2 placebo participants
per cohort) at dosages ranging from 9 to 900 mg;
part 2 was a multiple ascending dose (MAD)
study in four cohorts (8 active drug and 2 placebo participants per cohort) at dosages ranging
from 150–900 mg; and part 3 was a food effect
study. The primary objective of the study was to
assess the safety and tolerability of DM1157, and
the secondary objective was to characterize
DM1157 PK. Pre-defined study halting rules
included any subject developing a serious
adverse event (SAE) related to the study drug;
two or more subjects in any cohort experiencing
a grade 3 adverse event (AE) of the same type; or
any subject developing an episode of anaphylaxis within 24 h of study drug administration.
During the MAD arm, individual participants
were to be halted if they experienced an SAE
related to study drug or any other condition that
unduly increased the risk to the subject at the
site principal investigator’s discretion.
Ethics Approval
The study was approved by the Duke Institutional Review Board (Pro00091787), all subjects
provided written consent, and the trial was
conducted in accordance with the Declaration
of Helsinki.
Definitions of Adverse Events
Using protocol-defined adverse event grading, a
mild (grade 1) adverse event (AE) was defined as

an event that required minimal or no treatment
and did not interfere with a participant’s daily
activities; a moderate (grade 2) AE was defined
as that which resulted in a low level of inconvenience or concern with therapeutic intervention and may have caused some interference
with daily activities; a severe (grade 3) AE
interrupted the participant’s usual daily activities, may have required therapy or other treatment and was usually incapacitating.
Inclusion/Exclusion Criteria
Healthy male and non-pregnant females aged
18–45 years with body mass index 18–35 kg/m2
were eligible to participate. Subjects were
excluded if they had clinically significant electrocardiogram abnormalities at baseline, used
any prescription medication within 14 days
prior to study drug (excluding oral contraceptives), used non-prescription medication within
7 days of study drug and/or had significant
medical comorbidities or baseline laboratory
abnormalities.
PK Sampling and Analysis
During the SAD, plasma and whole-blood samples were collected on days 1, 2, 3, 4, 5 and 6 at
the following time points: pre-dose and at 0.5,
1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 and
120 h post-dose. Samples from participants were
included in the analysis if the participant had
received a complete DM1157 dose without
vomiting within 2 h and had at least one measureable concentration. PK samples were analyzed by Frontage Laboratories using liquid
chromatography tandem-mass spectrometry
(LC-MS/MS).
Noncompartmental analysis PK parameters
were determined using Phoenix WinNOnlin
(V8.1, Certara), including maximum drug concentration (Cmax), time to reach maximum
concentration (Tmax), area under the concentration vs. time curve from dosing through the
last measurable concentration (AUC0–last), area
under the concentration vs. time curve from
time 0 to infinity (AUC0–inf), apparent total
clearance after oral administration (CL/F) and
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apparent volume of distribution during terminal phase (Vz/F). For noncompartmental analysis, values below the quantifiable limit were
imputed as zero if there was no previous measurable concentration for the subject and
otherwise treated as missing.
Population PK (PopPK) analysis was conducted as part of an ad hoc interim analysis
after cohort 6 of the SAD. The analysis was
conducted using Phoenix NLME (V8.1) to estimate PopPK parameters and conduct dosing
simulations; 1-, 2- and 3-compartment models
and a variety of approaches for modeling nonlinearity were explored. Results below the
quantifiable limit (BQL) were included in the
analysis dataset and imputed as one-half the
limit of quantification. Modeling was conducted using total concentrations rather than
unbound concentrations; accordingly, saturable
protein binding was used empirically to predict
nonlinearity. The first order conditional estimation- extended least square method was used
for estimation, and the final model was selected
based on the lowest negative log likelihood,
Akaike information criterion and overall model
fit. The final model was evaluated using prediction-corrected visual predictive checks.
Thereafter, the final model was used to simulate
1000 time-concentration profiles for each dose.
Pointwise prediction bands were plotted using
the 2.5th and 97.5th percentiles for predicted
concentration at each time point.
Correlations between whole-blood DM1157
exposure (AUC) and clinical laboratory results
were explored using linear mixed effects models, and laboratory tests with significant
(p \ 0.01) main effects or time interactions with
AUC were visualized graphically.
Efficacy and Safety Exposure Targets
For dosing simulations, AUC0–120 h, a measure
of total exposure over three doses, was used to
assess the safety of planned MAD dosing (three
times daily for three consecutive days). Based
on exposures at which severe AEs occurred in
cohort 1–cohort 6, a safety target of AUC0–120 h \ 5560 h ng/ml was used. For efficacy, in vivo
experiments
using
whole
blood
from

humanized mice suggested an AUC0–24 h of
9892 h ng/ml following five doses (given daily
for five consecutive days) were required for
parasite clearance of a chloroquine-resistant
strain. Therefore, an efficacy target of day 5
AUC0-24 h [ 9892 h ng/ml was used.
Statistics
All AEs were coded using MedDRA dictionary
version 22.1. The number of AEs and number of
subjects with an AE were summarized by dose
group, MedDRA SOC and preferred term, maximum severity and relatedness to study product.
Relatedness was categorized as related or not
related. Summary statistics were computed for
change from baseline in clinical laboratory tests
by time point, severity and dose group. Summary statistics were also computed for change
in baseline vital signs and electrocardiogram
intervals. Clinical laboratory results, vital signs
and electrocardiogram intervals were graded
using a pre-defined toxicity table.

RESULTS
Demographics and Study Disposition
A total of 121 subjects were screened, 50 were
enrolled in the study, and 48 received study
drug. Of 50 subjects enrolled, 60% were males
and 40% were females. The majority of subjects
were black or African American (48%) or white
(32%), and most subjects were not Hispanic or
Latino (94%). The mean (range) demographics
were: age 30.7 years (19–45), weight 78.4 kg
(50.4–110) and body mass index 26.4 kg/m2
(18.6–33).
An ad hoc interim analysis of safety and PK
was conducted after dose escalation halting
rules were met in cohort 6 of the SAD arm. After
review, the safety monitoring committee recommended study termination due to safety.
The 900-mg SAD cohort, the MAD arm, and the
food study were not conducted.
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Table 1 Overall summary of adverse events by dose group
SAD
9 mg
(N = 6)
n (%)

SAD
27 mg
(N = 6)
n (%)

SAD
81 mg
(N = 6)
n (%)

SAD
150 mg
(N = 6)
n (%)

SAD
300 mg
(N = 6)
n (%)

SAD
600 mg
(N = 6)
n (%)

Placebo All
(N = 12) subjects
(N = 48)
n (%)
n (%)

At least one adverse
event

4 (67)

6 (100)

3 (50)

5 (83)

6 (100)

5 (83)

9 (75)

38 (79)

At least one related
adverse event

2 (33)

1 (17)

2 (33)

3 (50)

4 (67)

4 (67)

4 (33)

20 (42)

At least one mild (or
worse) related adverse
event

2 (33)

1 (17)

2 (33)

3 (50)

4 (67)

4 (67)

4 (33)

20 (42)

At least one moderate
(or worse) related
adverse event

–

–

–

1 (17)

2 (33)

3 (50)

–

6 (13)

At least one severe
related adverse event

–

–

–

–

–

3 (50)

–

3 (6)

Subjects with

N number of subjects in the safety population, SAD single ascending dose

Adverse Events
The overall summary of AEs by dose group is
presented in Table 1. Among 48 subjects in the
safety population (defined as subjects receiving
a dose), 38 (79%) experienced at least one AE.
Twenty subjects (42%) experienced at least one
mild or worse treatment-related AE, six subjects
(13%) experienced at least one moderate or
worse treatment-related AE, and three (6%)
subjects experienced at least one severe, treatment-related AE. All severe AEs occurred in the
600-mg dosing group. No deaths or serious
adverse events were reported in the study, and
no AEs led to early termination or withdrawal.
Of the seven moderate or severe AEs related to
treatment, participants experienced: moderate,
intermittent systolic hypertension, moderate
vomiting for 3 days, moderate acute inflammatory response for 3 days, moderate sinus bradycardia for 7 days, severe acute inflammatory
response (3 individuals) lasting 5 days for two
subjects and 10 days for one subject. The
inflammatory responses in the 300-mg and
600-mg cohorts generally coincided with

increased white blood cells on day 2 with transiently increased neutrophils, decreased lymphocytes and decreased platelets. The white
blood cell and neutrophil counts then
decreased by day 6 before approaching baseline
on day 14. Furthermore, several subjects in the
600-mg dosage group experienced elevations in
liver enzymes, most commonly a mild (n = 3) or
moderate (n = 1) elevation in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) on day 6. All elevations in liver
enzymes in the 600-mg cohort were deemed
related to study drug. All participants recovered
from these events. Representative plots of the
white blood cell count, AST and ALT results by
dose group are noted in Supplemental Figs.1–3.
Across all dosages, the mean (SD) change
from baseline for total leukocytes (109/l) was
1.58 (1.46) on day 2 and - 0.41 (1.43) on day 6.
The mean (SD) change from baseline for lymphocytes (109/l) was 0.61 (0.62) on day 2 and
- 0.07 (0.47) on day 6. The mean (SD) change
from baseline for platelets (109/l) was - 6.7
(19.3) on day 2 and - 20.1 (28.6) on day 6.
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Fig. 1 Whole-blood AUC vs. leukocyte count. AUC area under the curve for the time-concentration proﬁle

Regarding electrocardiogram measurements,
there was one AE for mild QTc prolongation in
the 150-mg dose group that was deemed unrelated to the study drug. No subjects who had
normal parameters at baseline developed clinically significant abnormalities post-baseline.
Exposure-Response Analysis
Figures 1, 2 and 3 characterize the relationship
between drug exposure in whole blood (AUC)

and total white blood count, lymphocyte count
and platelet count. We observed a trend toward
increased white blood cells on Day 2 and
decreased white blood cells on Days 3 and six
with whole-blood exposure. Similarly, there
appeared to be a decrease in both lymphocytes
and platelets with whole-blood exposure on
Days 3 and 6. Although statistically significant,
there was no apparent visual relationship
between whole-blood AUC and AST or ALT.
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Fig. 2 Whole-blood AUC vs. lymphocyte count. AUC area under the curve for the time-concentration proﬁle
PK Modeling and Simulation
Plasma samples from three participants who
received 9 mg and one participant who received
150 mg had no measurable DM1157 concentration and were excluded. Additionally, wholeblood samples from one participant who
received 9 mg and one who received 150 mg
had no measurable concentration and were
excluded. In total, 510 plasma samples from 32
subjects and 543 whole-blood samples from 34
participants were included in the PK analysis.

PK parameters in plasma from non-compartmental analysis are noted in Table 2,
whereas PK parameters in whole blood are
noted in Supplemental Table 1. Acceptance
criteria for estimation of the terminal slope of
the time-concentration profile (kz) were not met
in any subject (insufficient number of half-lives
observed after Tmax) with plasma concentrations and so the terminal phase PK parameters
(half-life, CL/F, Vz/F, AUC0–inf) could not be
analyzed. The median Tmax in plasma ranged
from 0.5 to 2 h, and the geometric mean Cmax
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Fig. 3 Whole-blood AUC vs. platelet count. AUC area under the curve for the time-concentration proﬁle
was 2.48–613.5 ng/ml. Both Cmax and AUC0–last
appeared to increase in a non-linear (greater
than dose proportional) fashion with dosage.
Furthermore, exposure was higher for whole
blood compared to plasma. For the 600-mg SAD
cohort, the mean estimated half-life in whole
blood was 29.53 h; CL/F was 53.23 l/h; Vz/F was
2268.06 l. The time-concentration profile in
whole blood is depicted in Supplemental Fig. 4.
The final PopPK model was a two-compartment model with saturable protein binding, a
delay in absorption and estimated between-

subject variability for each parameter (exponential model). The prediction-corrected visual
predictive checks show that the model can
adequately predict the median trend and variability of the observed data (Supplemental
Figs. 5–8).
Using the final PopPK model, dosing simulations were conducted for 1000 virtual subjects
per dose, including intermediate doses of
222 mg and 450 mg that were not assessed in
the trial. The simulations suggested that none
of the virtual subjects met both the safety and

5425.3 (64)

9.04 (64)

2624.1 (31)

8.75 (31)
Values of GM (CV %) are shown, except for Tmax for which values of median (min–max) are shown
Values are geometric mean (% coefﬁcient of variation), except for Tmax (median [range])
PK pharmacokinetic, SAD single ascending dose

4.32 (61)
1.92 (84)
0.11 (109)
AUC(0–last)/dose (h ng/ml/mg)

0.49 (80)

648.0 (61)
155.1 (84)
1.01 (109)
AUC(0–last) (h ng/ml)

13.18 (80)

1.50 (0.50–2.0)
2.00 (1.0–2.0)
0.50 (0.50–1.0)
Tmax (h)

0.74 (0.50–4.0)

1.00 (1.0–2.0)

1.03 (1.0–4.0)

1.02 (48)
0.75 (32)
0.28 (20)
Cmax/dose (ng/ml/mg)

0.20 (33)

0.33 (29)

0.52 (56)

613.5 (48)
225.2 (32)
2.48 (20)
Cmax (ng/ml)

5.40 (33)

27.03 (29)

78.59 (56)

SAD 600 mg
SAD 9 mg

SAD 27 mg

efficacy criteria. The 9-mg and 27-mg dosages
were predicted to meet safety criteria in 100% of
simulations, 81 mg in 97% of simulations,
150 mg in 55% of simulations, 300 mg in 2% of
simulations, and 600 mg was not predicted to
meet the safety target in any simulations. From
an efficacy standpoint, the primary systemic
exposure efficacy target was reached 1% of the
time at the 150-mg dosage, 36% of the time for
the 300-mg dosage and 94% of the time for the
600-mg dosage. Results of the dosing simulations are noted in Fig. 4.

DISCUSSION

PK parameter

Table 2 Summary statistics for DM1157 PK parameters in plasma

SAD 81 mg

SAD 150 mg

SAD 300 mg
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In this first-in-human, phase 1 trial of DM1157
in healthy volunteers, we observed mild to
moderate AEs in the 300-mg dosage group and
more severe symptoms (e.g., headache, nausea,
vomiting, fever, tachycardia, chills) in the
600-mg dosage group. In addition to this doseadverse event relationship, all participants
reported a comparable timeline for their symptoms, starting on the evening of day 2 postdose, worsening on day 3 and then gradual
resolution. There were no similar symptoms in
study staff, symptoms did not occur in subjects
dosed with placebo, and testing for viral illnesses was negative in selected participants.
Overall, these findings suggest that the symptoms were study drug-related and not
attributable to a communicable illness. Similar
inflammatory responses have not been observed
with chloroquine analogs, with typical adverse
events being lightheadedness/dizziness, gastrointestinal distress, tinnitus, rash or vision
changes [3]. However, agranulocytosis has been
reported with the chloroquine analog amodiaquine [4]; reversible hepatotoxicity has been
reported with administration of chloroquine in
combination with proguanil [5] and very rarely
with use of hydroxychloroquine in rheumatologic and dermatologic disease [6, 7]. Hepatotoxicity
may
reflect
accumulation
of
intracellular chloroquine analogs within lysosomes, a process that interferes with the lysosomal acidification that is necessary for
proteolysis, endocytosis, exosome release and
phagolysosomal fusion [8, 9].
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Fig. 4 Dosing simulations. Model predicted AUC on the
Y axis with doses on X axis. Box plots represent the mean
(symbols), median (solid line), interquartile range (IQR;
box) and min/max values within the 1.5*IQR boundary

(whiskers). Left: Efﬁcacy target. Right: Safety target. AUC
area under the curve for the time-concentration proﬁle

Population PK/PD models are powerful
mathematical tools that relate drug concentration to effect and can be used to predict drug
exposure at different dosages. The United States
Food and Drug Administration routinely
encourages the use of this modeling and simulation approach to guide drug development
[10]. This study provides an important example
of how modeling and simulation can be used to
guide clinical trial design and study management. Specifically, we used a population PK
model to quantitatively assess whether the
DM1157 exposure needed for P. falciparum
inhibition was achievable at safe doses. We
found that there was no dose where both the
safety and efficacy targets were simultaneously
achieved; conversely, 27 mg was the highest
dosage at which the model predicted patients
would consistently maintain safe exposure.
Accordingly, the combination of stopping rules
and interim assessment with pharmacokinetic
modeling resulted in the early termination of a
study that could otherwise have resulted in
significant harm to participants without any
benefit to the clinical development of the
therapeutic.
There are a few limitations of the study. First,
there were limited in vivo experimental data to
definitely determine the target therapeutic
exposure of DM1157. Despite this potential

limitation, several modeling exercises suggested
that safe and effective dosages could not be
simultaneously achieved, even if alternative
exposure targets were used. Second, we could
not quantify PK parameters for all subjects
because of difficulty estimating the terminal
elimination profile. However, the population
PK model evaluation methods still suggested
that the PK model fit the data well and therefore
is unlikely to impact the study conclusions.

CONCLUSION
In this first-in-human, phase 1 trial of DM1157
in healthy volunteers, we observed dose-dependent adverse events consistent with an
acute inflammatory response. By pre-defining
dosage escalation stopping rules and conducting an interim PK/PD analysis, we were able to
address the safety signals and determine that
the study would be unable to safely achieve a
dosage needed to observe an anti-malarial
effect, thereby providing strong rationale to
halt the study. This study provides an important
example of the risks and challenges of conducting early phase research as well as the role
of modeling and simulation to optimize participant safety.
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